Prognostic significance of Pleural Fluid triglyceride levels based on a low-Fat Diet Management Strategy in patients with Chylothorax following pulmonary resection.
Chylothorax
Low-fat diet
Pleural fluid
Pulmonary resection
Triglyceride level
Journal
Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113
Informations de publication
Date de publication:
20 Jun 2024
20 Jun 2024
Historique:
received:
26
03
2024
accepted:
14
06
2024
medline:
21
6
2024
pubmed:
21
6
2024
entrez:
20
6
2024
Statut:
epublish
Résumé
Chylothorax is a postoperative complication in patients with lung cancer. Diet-control approaches have been the mainstay for managing this condition. However, a surgical intervention is needed for the patients if conservative treatment is ineffective. Because of the lack of accurate indicators to assess the prognosis of the postoperative complication at an early stage, the criteria of surgical treatment were not consistent. We reviewed 2942 patients who underwent pulmonary resection and lymph node dissection for primary lung cancer at our hospital between March 2021 and December 2022. The prognostic implications of clinical indicators were assessed in patients with postoperative chylothorax who were managed with a low-fat diet. Binary logistic regression was used to explore the predictive value of these indicators for patient prognosis. Postoperative chylothorax occurred in 108 patients and 79 patients were treated with a low-fat diet management while 29 patients were managed with TPN. In contrast to drainage volume, the pleural effusion triglyceride level after 2 days of low-fat diet exhibited enhanced predictive efficacy in predicting patient prognosis. When the pleural fluid triglyceride level of 1.33 mmol/L was used as the diagnostic threshold for prognosis, the sensitivity and specificity reached 100% and 80.6%, respectively. The pleural effusion triglyceride level after 2 days of low-fat diet can serve as a valuable prognostic indicator in patients undergoing lung surgery and experiencing chylothorax. This predictive approach will help thoracic surgeons to identify patients with poor prognosis in a timely manner and make decision to perform necessary surgical interventions.
Sections du résumé
BACKGROUND
BACKGROUND
Chylothorax is a postoperative complication in patients with lung cancer. Diet-control approaches have been the mainstay for managing this condition. However, a surgical intervention is needed for the patients if conservative treatment is ineffective. Because of the lack of accurate indicators to assess the prognosis of the postoperative complication at an early stage, the criteria of surgical treatment were not consistent.
METHODS
METHODS
We reviewed 2942 patients who underwent pulmonary resection and lymph node dissection for primary lung cancer at our hospital between March 2021 and December 2022. The prognostic implications of clinical indicators were assessed in patients with postoperative chylothorax who were managed with a low-fat diet. Binary logistic regression was used to explore the predictive value of these indicators for patient prognosis.
RESULTS
RESULTS
Postoperative chylothorax occurred in 108 patients and 79 patients were treated with a low-fat diet management while 29 patients were managed with TPN. In contrast to drainage volume, the pleural effusion triglyceride level after 2 days of low-fat diet exhibited enhanced predictive efficacy in predicting patient prognosis. When the pleural fluid triglyceride level of 1.33 mmol/L was used as the diagnostic threshold for prognosis, the sensitivity and specificity reached 100% and 80.6%, respectively.
CONCLUSIONS
CONCLUSIONS
The pleural effusion triglyceride level after 2 days of low-fat diet can serve as a valuable prognostic indicator in patients undergoing lung surgery and experiencing chylothorax. This predictive approach will help thoracic surgeons to identify patients with poor prognosis in a timely manner and make decision to perform necessary surgical interventions.
Identifiants
pubmed: 38902767
doi: 10.1186/s13019-024-02850-4
pii: 10.1186/s13019-024-02850-4
doi:
Substances chimiques
Triglycerides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
337Informations de copyright
© 2024. The Author(s).
Références
Nair SK, Petko M, Hayward MP. Aetiology and management of chylothorax in adults. Eur J Cardiothorac Surg. 2007;32:362–69.
doi: 10.1016/j.ejcts.2007.04.024
pubmed: 17580118
Chen C, Wang Z, Hao J, Hao X, Chen J, Chen N, et al. Chylothorax after Lung Cancer surgery: a key factor influencing prognosis and quality of life. Ann Thorac Cardiovasc Surg. 2020;26:303–10.
doi: 10.5761/atcs.ra.20-00039
pubmed: 32611931
pmcid: 7801173
Akin H, Olcmen A, Isgorucu O, Denizkiran I, Dincer I. Approach to patients with chylothorax complicating pulmonary resection. Thorac Cardiovasc Surg. 2012;60:135–39.
doi: 10.1055/s-0030-1270990
pubmed: 21557161
Liu CY, Hsu PK, Huang CS, Sun YH, Wu YC, Hsu WH. Chylothorax complicating video-assisted thoracoscopic surgery for non-small cell lung cancer. World J Surg. 2014;38:2875–81.
doi: 10.1007/s00268-014-2699-4
pubmed: 24989031
Petrella F, Casiraghi M, Radice D, Bertolaccini L, Spaggiari L. Treatment of Chylothorax after Lung Resection: indications, timing, and outcomes. Thorac Cardiovasc Surg. 2020;68:520–24.
doi: 10.1055/s-0040-1710071
pubmed: 32492713
Kutlu CA, Sayar A, Olgac G, Akin H, Olcmen A, A Bedirhan M, et al. Chylothorax: a complication following lung resection in patients with NSCLC - chylothorax following lung resection. Thorac Cardiovasc Surg. 2003;51:342–45.
doi: 10.1055/s-2003-45423
pubmed: 14669132
Uchida S, Suzuki K, Hattori A, Takamochi K, Oh S. Surgical intervention strategy for postoperative chylothorax after lung resection. Surg Today. 2016;46:197–202.
doi: 10.1007/s00595-015-1183-6
pubmed: 26036222
Shimizu K, Yoshida J, Nishimura M, Takamochi K, Nakahara R, Nagai K. Treatment strategy for chylothorax after pulmonary resection and lymph node dissection for lung cancer. J Thorac Cardiovasc Surg. 2002;124:499–502.
doi: 10.1067/mtc.2002.124386
pubmed: 12202866
Yasuura Y, Konno H, Hayakawa T, Terada Y, Mizuno K, Kayata H, et al. Chylothorax after pulmonary resection and lymph node dissection for primary lung cancer; retrospective observational study. J Cardiothorac Surg. 2022;17:11.
doi: 10.1186/s13019-022-01758-1
pubmed: 35065672
pmcid: 8783405
Cho HJ, Kim DK, Lee GD, Sim HJ, Chio SH, Kim HR, et al. Chylothorax complicating pulmonary resection for lung cancer: effective management and pleurodesis. Ann Thorac Surg. 2014;97:408–13.
doi: 10.1016/j.athoracsur.2013.10.065
pubmed: 24365215
Teba L, Dedhia HV, Bowen R, Alexander JC. Chylothorax review. Crit Care Med. 1985;13:49–52.
doi: 10.1097/00003246-198501000-00013
pubmed: 3917388
Takuwa T, Yoshida J, Ono S, Hishida T, Nishimura M, Aokage K, et al. Low-fat diet management strategy for chylothorax after pulmonary resection and lymph node dissection for primary lung cancer. J Thorac Cardiovasc Surg. 2013;146:571–4.
doi: 10.1016/j.jtcvs.2013.04.015
pubmed: 23764409
Maldonado F, Hawkins FJ, Daniels CE, Doerr CH, Decker PA, Ryu JH. Pleural fluid characteristics of chylothorax. Mayo Clin Proc. 2009;84(2):129 – 33.
Cerfolio RJ, Bryant AS. Results of a prospective algorithm to remove chest tubes after pulmonary resection with high output. J Thorac Cardiovasc Surg. 2008;135:269–73.
doi: 10.1016/j.jtcvs.2007.08.066
pubmed: 18242249